Clinical Scorecard: This Week’s Biopharma News: EU Clears First Pertuzumab Biosimilar
At a Glance
| Category | Detail |
|---|---|
| Condition | HER2-positive breast cancer |
| Key Mechanisms | Pertuzumab biosimilar POHERDY shows high similarity to Roche’s PERJETA. |
| Target Population | Patients with HER2-positive breast cancer in Europe. |
| Care Setting | Oncology care settings, including metastatic, neoadjuvant, and adjuvant treatment. |
Key Highlights
- EU approves first pertuzumab biosimilar, POHERDY.
- Biosimilar authorized for all indications of the reference product.
- Approval based on comprehensive comparability package.
- Supports wider access to HER2-targeted therapy in Europe.
- Organon gains exclusive commercialization rights outside China.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of HER2-positive breast cancer.
Management
- Use of POHERDY in metastatic, neoadjuvant, and adjuvant settings.
Monitoring & Follow-up
- Monitor for efficacy and safety similar to reference product.
Risks
- Potential immunogenicity and safety concerns similar to reference product.
Patient & Prescribing Data
Adults with HER2-positive breast cancer.
POHERDY provides an alternative to Roche’s PERJETA.
Clinical Best Practices
- Ensure comprehensive patient assessment for HER2 positivity.
- Consider biosimilar options to enhance treatment accessibility.
- Monitor patient response and adjust treatment as necessary.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
